Recent Finacing
Recent Raise
BITT develops antagonist monoclonal antibodies against TNF superfamily receptors using its DOMab™ platform; lead TNFR2 antibody BIR2101 is in Phase I while CD40 and other programs advance preclinical/IND stages.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Boston Immune Technologies & Therapeutics.
